NeuroDerm (Israel)

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial

Alberto J. Espay, Fabrizio Stocchi, Rajesh Pahwa et al. · The Lancet Neurology · 2024 · 60 citations

Parkinson Disease, Clinical Neurology, Multicentre Trial +6

Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test

Shoji Hirasaki, Seiyuu Suzuki, Shigeki Umemura et al. · World Journal of Gastroenterology · 2008 · 37 citations · Full text

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1<scp>‐Year</scp> Data from the <scp>Open‐Label BeyoND</scp> Study

Werner Poewe, Fabrizio Stocchi, David Arkadir et al. · Movement Disorders · 2021 · 36 citations · Full text

Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs

Yuval Ramot, Abraham Nyska, Robert R. Maronpot et al. · Toxicologic Pathology · 2017 · 31 citations

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Peter A. LeWitt, Fabrizio Stocchi, David Arkadir et al. · Frontiers in Neurology · 2022 · 28 citations · Full text